Hepatitis C: An economic evaluation of extended treatment with interferon

Medical Journal of Australia

Volumn 171, Issue 4, 1999, Pages 189-193

  Shiell, Alan ^a   Brown, Sue ^b   Farrell, Geoff C ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Medical Benefits Fund of Australia   (Australia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON;

ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HUMAN; MEDICAL LITERATURE; PATIENT SELECTION; QUALITY OF LIFE; TIME;

EID: 0033575707     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1999.tb123595.x     Document Type: Article

References (26)

1. Australian Health Ministers' Advisory Council. National Hepatitis C Action Plan, October 1994. Canberra; AGPS, 1994.
2. Garcia de Ancos JL, Roberts JA, Dusheiko GM. An economic evaluation of the costs of α-interferon treatment for chronic active hepatitis due to hepatitis B or C virus. J Hepatol 1990; 11: S11-S18,
3. Shiell A, Briggs A, Farrell G. The cost-effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust 1994; 160: 268-272.
4. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995; 22: 1863-1873.
5. Joliet E, Vanlemmens C, Kerleau M, et al. Cost-effectiveness analysis of the treatment of chronic hepatitis C. Gastroenterol Clin Biol 1997; 21: 336-338.
6. Bennet WG, Inoue Y, Beck R, et al. Estimates of the cost-effectiveness of a single course of interferon-α 2b in patients with histologically mild hepatitis C. Ann Intern Med 1997; 127: 855-865.
7. Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866-874.
8. National Institutes of Health Consensus Development Panel statement: management of hepatitis C. Hepatology 1997; 26(3 Suppl 1): 2S-10S.
9. Fattovitch G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterotogy 1997; 112: 463-472.
10. Australian Bureau of Statistics. Deaths: Australia 1994. Canberra: ABS, 1994, (Catalogue No. 3302.0.)
11. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789.
12. Carithers RL Jr, Sugano D, Bayliss M. Health assessment for chronic HCV infection: results of quality of life. Dig Dis Sci 1996; 41: 75S-80S.
13. Davis GL, Balart LA, Schiff ER, et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther 1994; 16: 334-343.
14. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-212.
15. National Health and Medical Research Council. A strategy for the detection and management of hepatitis C in Australia. Canberra: NHMRC/AGPS, 1997.
16. Commonwealth Department of Health and Family Services. Medical Benefits Schedule. Nov 1996. Canberra; AGPS, 1996.
17. Commonwealth Department of Health, Housing, Local Government and Community Services. Manual of Resource Items and their Associated Costs. Canberra: AGPS, November 1993.
18. Drummond MF, Brandt A, Luce B, Rovira J. Standardising methodologies for economic evaluation in health care. Int J Technol Assess Health Care 1993; 9: 26-36.
19. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 230.
20. AHMAC Breast Cancer Screening Evaluation Committee. Breast screening in Australia: future directions. Canberra: Australian Institute of Health and Welfare, 1990.
21. AHMAC Cervical Cancer Screening Evaluation Committee. Cervical Screening in Australia: options for change. Canberra: Australian Institute of Health and Welfare, 1991.
22. Salkeld G, Davey PD, Arnolda G. A critical review of health-related economic evaluations in Australia: implications for health policy. Health Policy 1995; 31: 111-125.
23. Birch S, Donaldson C. Cost-benefit analysis: dealing with the problems of indivisible projects and fixed budgets. Health Policy 1987; 7: 61-72
24. Bennet WG, Pauker SG, Davis GL, Wong JB. Modeling therapeutic benefit in the midst of uncertainty: therapy for hepatitis C. Dig Dis Sci 1996; 41: 56S-62S.
25. Koff RS, Seeff LB. Economic modeling of treatment of chronic hepatitis B and chronic hepatitis C: promises and limitations. Hepatology 1995; 22: 1880-1885.
26. Owens DK. In the eye of the beholder: assessment of health-related quality of life. Hepatology 1998; 27: 292-293.